Telomir-Zn shows dose-dependent survival improvement in Wilson's disease model
Telomir Pharmaceuticals announced peer-reviewed publication of preclinical data demonstrating that Telomir-Zn produced dose-dependent survival improvements and reduced hepatic copper burden in a Wilson's disease model. The findings support the drug candidate's biological activity
View filing at SEC.gov →